Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Body Mass Index | 1 | 2020 | 4306 | 0.33 | Why? |
| Public Health Surveillance | 7 | 2021 | 3129 | 0.33 | Why? |
| HIV | 3 | 2021 | 1116 | 0.33 | Why? |
| Uterine Cervical Neoplasms | 3 | 2018 | 842 | 0.29 | Why? |
| Coffee | 1 | 2021 | 79 | 0.21 | Why? |
| HIV Infections | 7 | 2021 | 11620 | 0.21 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.19 | Why? |
| Vegetables | 1 | 2021 | 340 | 0.18 | Why? |
| Meat | 1 | 2021 | 380 | 0.18 | Why? |
| Viral Load | 4 | 2020 | 15850 | 0.14 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.14 | Why? |
| Health Policy | 3 | 2021 | 6242 | 0.12 | Why? |
| Papillomavirus Vaccines | 1 | 2017 | 405 | 0.12 | Why? |
| Hospitals, Urban | 1 | 2017 | 950 | 0.12 | Why? |
| Anti-Retroviral Agents | 2 | 2017 | 1099 | 0.12 | Why? |
| Longitudinal Studies | 6 | 2021 | 9893 | 0.11 | Why? |
| Nutritional Status | 1 | 2021 | 1403 | 0.11 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.11 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.09 | Why? |
| Diagnostic Imaging | 1 | 2017 | 1044 | 0.09 | Why? |
| Papillomavirus Infections | 1 | 2017 | 861 | 0.09 | Why? |
| Early Detection of Cancer | 2 | 2018 | 1956 | 0.09 | Why? |
| Sputum | 1 | 2017 | 1720 | 0.09 | Why? |
| Feeding Behavior | 1 | 2021 | 1909 | 0.09 | Why? |
| Diet | 1 | 2021 | 2052 | 0.09 | Why? |
| Genotype | 1 | 2020 | 4697 | 0.09 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.09 | Why? |
| Tuberculosis, Pulmonary | 1 | 2017 | 1171 | 0.08 | Why? |
| Public Health | 5 | 2021 | 16359 | 0.07 | Why? |
| Atrial Fibrillation | 1 | 2018 | 2320 | 0.06 | Why? |
| Risk Assessment | 2 | 2017 | 25439 | 0.06 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2017 | 3388 | 0.06 | Why? |
| Forecasting | 1 | 2017 | 4492 | 0.06 | Why? |
| CD4 Lymphocyte Count | 2 | 2017 | 1517 | 0.06 | Why? |
| Gibraltar | 1 | 2021 | 15 | 0.06 | Why? |
| Asia, Central | 1 | 2021 | 18 | 0.06 | Why? |
| Azerbaijan | 1 | 2021 | 40 | 0.06 | Why? |
| Phylogeny | 1 | 2020 | 13341 | 0.06 | Why? |
| Georgia (Republic) | 1 | 2021 | 43 | 0.06 | Why? |
| Kosovo | 1 | 2021 | 44 | 0.06 | Why? |
| Polynesia | 1 | 2021 | 62 | 0.06 | Why? |
| Armenia | 1 | 2021 | 89 | 0.06 | Why? |
| Australasia | 1 | 2021 | 89 | 0.06 | Why? |
| Far East | 1 | 2021 | 125 | 0.05 | Why? |
| Food Handling | 1 | 2021 | 103 | 0.05 | Why? |
| Cyprus | 1 | 2021 | 186 | 0.05 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.05 | Why? |
| Registries | 4 | 2021 | 12327 | 0.05 | Why? |
| Nigeria | 2 | 2018 | 2292 | 0.05 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.05 | Why? |
| Female | 15 | 2021 | 380317 | 0.05 | Why? |
| Education, Distance | 1 | 2020 | 4956 | 0.05 | Why? |
| Asia, Southeastern | 1 | 2021 | 390 | 0.05 | Why? |
| Africa, Northern | 1 | 2021 | 539 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Defective Viruses | 1 | 2018 | 98 | 0.05 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.05 | Why? |
| Philippines | 1 | 2021 | 568 | 0.04 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.04 | Why? |
| Survival | 1 | 2017 | 53 | 0.04 | Why? |
| Humans | 22 | 2022 | 930598 | 0.04 | Why? |
| Administrative Personnel | 1 | 2021 | 326 | 0.04 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.04 | Why? |
| Adult | 9 | 2021 | 244371 | 0.04 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.04 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.04 | Why? |
| Benchmarking | 1 | 2021 | 627 | 0.04 | Why? |
| Male | 11 | 2021 | 367725 | 0.04 | Why? |
| Russia | 1 | 2021 | 989 | 0.04 | Why? |
| Indonesia | 1 | 2021 | 1022 | 0.04 | Why? |
| Malaysia | 1 | 2021 | 1116 | 0.04 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.04 | Why? |
| Middle East | 1 | 2021 | 1418 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Africa South of the Sahara | 1 | 2020 | 1335 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2020 | 53120 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Molecular Epidemiology | 1 | 2021 | 1638 | 0.04 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2017 | 17020 | 0.03 | Why? |
| Retrospective Studies | 3 | 2022 | 105322 | 0.03 | Why? |
| Asia | 1 | 2021 | 2399 | 0.03 | Why? |
| Biological Specimen Banks | 1 | 2021 | 1142 | 0.03 | Why? |
| Denmark | 1 | 2021 | 2654 | 0.03 | Why? |
| Papillomaviridae | 1 | 2017 | 404 | 0.03 | Why? |
| HIV-1 | 2 | 2018 | 3365 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.03 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 952 | 0.03 | Why? |
| Counseling | 1 | 2018 | 747 | 0.03 | Why? |
| Incidence | 3 | 2021 | 25622 | 0.03 | Why? |
| Risk Factors | 5 | 2021 | 71621 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Bias | 1 | 2017 | 1109 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Case-Control Studies | 2 | 2022 | 17671 | 0.03 | Why? |
| United States | 4 | 2020 | 46150 | 0.03 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.03 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.03 | Why? |
| Breast Feeding | 1 | 2021 | 1585 | 0.03 | Why? |
| RNA, Viral | 1 | 2018 | 32276 | 0.03 | Why? |
| Turkey | 1 | 2021 | 3937 | 0.03 | Why? |
| Whole Genome Sequencing | 1 | 2020 | 3239 | 0.02 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.02 | Why? |
| England | 1 | 2021 | 5116 | 0.02 | Why? |
| Prospective Studies | 3 | 2017 | 43301 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.02 | Why? |
| Patient Education as Topic | 1 | 2017 | 1476 | 0.02 | Why? |
| Self Report | 1 | 2018 | 3802 | 0.02 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.02 | Why? |
| Health Education | 1 | 2017 | 1539 | 0.02 | Why? |
| Anti-HIV Agents | 1 | 2018 | 2209 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Models, Biological | 1 | 2020 | 4907 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.02 | Why? |
| Referral and Consultation | 1 | 2018 | 4816 | 0.01 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.01 | Why? |
| United Kingdom | 1 | 2021 | 18046 | 0.01 | Why? |
| Treatment Outcome | 2 | 2017 | 51732 | 0.01 | Why? |
| Time-to-Treatment | 1 | 2017 | 5883 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 9335 | 0.01 | Why? |
| Adolescent | 2 | 2022 | 86841 | 0.01 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.01 | Why? |
| Aged | 3 | 2021 | 215776 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2022 | 25288 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.01 | Why? |
| Health Personnel | 1 | 2018 | 29646 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
Achenbach's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(134)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(103)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_